Abstract
Following intranasal administration, the peptides' effects could remain either the same as following an invasive administration (ACTH4-10) which is important for clinical application, or enhanced and prolonged (demorphin and argynilvasopressin analogue), or modified (beta-casomorphin-7). Techniques of improvement of the peptides' regulatory efficacy through protection against the protease action, are discussed. Peptide protection by introducing D-aminoacid's isomers into its molecule or addition of proline-rich sequences were compared. The latter technique seems to be more effective.
MeSH terms
-
Administration, Intranasal
-
Adrenocorticotropic Hormone / administration & dosage
-
Adrenocorticotropic Hormone / analogs & derivatives
-
Adrenocorticotropic Hormone / pharmacology
-
Animals
-
Arginine Vasopressin / administration & dosage
-
Arginine Vasopressin / analogs & derivatives
-
Arginine Vasopressin / pharmacology
-
Avoidance Learning / drug effects
-
Behavior, Animal / drug effects
-
Endorphins / administration & dosage
-
Endorphins / pharmacology
-
Injections, Intraperitoneal
-
Male
-
Neuroprotective Agents / administration & dosage*
-
Neuroprotective Agents / pharmacology
-
Oligopeptides / administration & dosage*
-
Oligopeptides / pharmacology
-
Opioid Peptides
-
Pain Measurement
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / pharmacology
-
Rats
-
Rats, Wistar
Substances
-
Endorphins
-
Neuroprotective Agents
-
Oligopeptides
-
Opioid Peptides
-
Peptide Fragments
-
Arginine Vasopressin
-
dermorphin
-
beta-casomorphin 7
-
ACTH (4-7), Pro-Gly-Pro-
-
Adrenocorticotropic Hormone